Acrux Posts Strong Half-Year Profit Rebound Despite Lower Asset Backing

An announcement from Acrux ( (AU:ACR) ) is now available.

Acrux Limited reported a strong improvement in financial performance for the half-year ended 31 December 2025, with revenues from ordinary activities rising 109% to A$3.57 million. Net profit attributable to members also more than doubled to A$165,000, although no dividends were declared for the period.

Despite the profit rebound, the company’s net tangible asset backing per share fell to 0.21 cents from 0.67 cents a year earlier, indicating a weaker asset base on a per-share basis. The reviewed half-year figures highlight both the company’s accelerating operational momentum and a capital structure that investors will watch closely as Acrux pursues further growth.

The most recent analyst rating on (AU:ACR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.

More about Acrux

Acrux Limited is an Australian company operating in the pharmaceutical and life sciences sector. The company focuses on developing and commercialising healthcare products, with revenues derived from ordinary operating activities rather than one-off items, positioning it as a small but growing player in its market.

Average Trading Volume: 240,490

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$5.75M

For an in-depth examination of ACR stock, go to TipRanks’ Overview page.